Legend Biotech Reports First Quarter 2023 Results and Recent

New and updated data from the CARTITUDE Clinical Development Program and LEGEND-2 study evaluating ciltacabtagene autoleucel will be presented at the 2023 American Society of Clinical Oncology ... | May 18, 2023

Related Keywords

New Jersey , United States , Ying Huang , Legend Biotech Corporation , Development Expenses , Twitter , Drug Administration , Exchange Commission On , Linkedin , Janssen Biotech Inc , Legend Biotech , Chief Executive Officer , Quarter Ended March , Cash Equivalents , Time Deposits , Short Term Investments , Janssen Biotech , Janssen Agreement , Distribution Expenses , Value Gain , Warrant Liability , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Legend Biotech Corporation Stock Exchange , News , Information , Press Release , Few , End , Pdated , Data , Rom , The , Artitude , Linical , Development , Program , Study , Valuating , Ciltacabtagene , Utoleucel , Hill , He , Resented , It , 023 , American , Society , F , Ncology Legn Us52490g1022 ,